BAYER RAPIDLAB 1200 SYSTEM
Device Facts
| Record ID | K031560 |
|---|---|
| Device Name | BAYER RAPIDLAB 1200 SYSTEM |
| Applicant | Bayer Healthcare, LLC |
| Product Code | CHL · Clinical Chemistry |
| Decision Date | Dec 17, 2003 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1120 |
| Device Class | Class 2 |
Indications for Use
The Rapidlab 1200 system series is intended for in vitro diagnostic use by healthcare professionals in the quantitative testing of samples of whole blood for the following parameters: partial pressure of carbon dioxide; partial pressure of oxygen; pH; sodium; potassium; ionized calcium; chloride; glucose; lactate; CO-oximetry parameters (tHb, FO2Hb, FCOHb, FMetHb, FHHb).
Device Story
Rapidlab 1200 System is an in vitro diagnostic analyzer for whole blood samples (arterial, venous, capillary). It measures blood gases, electrolytes, metabolites, and CO-oximetry parameters. The device uses electrochemical (potentiometry, amperometry) and optical (spectral absorption) sensors to convert biological sample inputs into electrical signals, which are then processed into quantitative concentration values. Operated by healthcare professionals in laboratory settings, the system provides results to clinicians to aid in the diagnosis and management of life-threatening conditions like acid-base disturbances, electrolyte imbalances, and metabolic disorders. It features connectivity to hospital LIS/HIS systems via network ports and the Rapidlink information management system. The output allows clinicians to make immediate decisions regarding patient treatment and correction of pathophysiologic states.
Clinical Evidence
No clinical data provided; substantial equivalence is based on technological characteristics and bench testing of measurement performance using electrochemical and optical methods.
Technological Characteristics
Measurement technology based on electrochemical (potentiometry, amperometry) and optical (spectral absorption) phenomena. Analyzes whole blood for gases, electrolytes, metabolites, and CO-oximetry. Connectivity via network interface ports to LIS/HIS and Rapidlink information management system. Benchtop form factor.
Indications for Use
Indicated for healthcare professionals to quantitatively test whole blood for blood gases (pH, pCO2, pO2), electrolytes (Na+, K+, Cl-, Ca++), metabolites (glucose, lactate), and co-oximetry parameters (tHb, FO2Hb, FCOHb, FMethb, FHHb) to aid in the diagnosis and treatment of acid-base disturbances, electrolyte imbalances, metabolic disorders, anemia, and carbon monoxide or sulfhemoglobin poisoning.
Regulatory Classification
Identification
A blood gases (PCO2 , PO2 ) and blood pH test system is a device intended to measure certain gases in blood, serum, plasma or pH of blood, serum, and plasma. Measurements of blood gases (PCO2 , PO2 ) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances.
Predicate Devices
Related Devices
- K962021 — CIBA CORNING 348 SYSTEM · Ciba Corning Diagnostics Corp. · Jun 24, 1996
- K061730 — OSMETECH OPTI R CRITICAL CARE ANALYZER, MODEL GD7044 · Osmetech, Inc. · Aug 4, 2006
- K041874 — ABL800 FLEX · Radiometer Medical Aps · Oct 8, 2004
Submission Summary (Full Text)
{0}
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
DEVICE AND INSTRUMENT TEMPLATE
A. 510(k) Number:
k031560
B. Analyte:
Partial pressure of carbon dioxide, Partial pressure of oxygen, pH, sodium, potassium, ionized calcium, chloride, glucose, lactate, and co-oximetry parameters (tHb, $\mathrm{FO}_2\mathrm{Hb}$, FCOHb, FMethb, FHHb).
C. Type of Test:
Ion selective electrode – Potassium, Chloride, Sodium, Calcium, and pH
Potentiometric method – pCO2
Amperiometric method – pO2
Enzymatic – Lactic Acid, Glucose
Spectral absorbency – CO-oximetry parameters
D. Applicant:
Bayer HealthCare, Diagnostic Division
E. Proprietary and Established Names:
Bayer Rapidlab 1200 System Series
F. Regulatory Information:
1. Regulation section:
21 CFR 862.1120; 21 CFR 862.1145; 21 CFR 862.1170; 21 CFR 862.1600; 21 CFR 862.1665; 21 CFR 862.1345; 21 CFR 862.1450; 21 CFR 864.5620.
2. Classification:
Class II; Class I
3. Product Code:
Blood Gases (pCO₂, pO₂) & pH-CHL; Calcium - JFP; Chloride - CGZ; Potassium - CEM; Sodium - JGS; Glucose - CGA; Lactic Acid - KHP; Hemoglobin - GKR
4. Panel:
75 Chemistry; 81 Hematology
G. Intended Use:
1. Intended use(s):
Refer to Indications for Use
2. Indication(s) for use:
The Rapidab 1200 system series is intended for in vitro diagnostic use by healthcare professionals in the quantitative testing of samples of whole blood for the following parameters:
Partial pressure of carbon dioxide, Partial pressure of oxygen, pH, sodium, potassium, ionized calcium, chloride, glucose, lactate, and co-oximetry parameters (tHb, $\mathrm{FO}_2\mathrm{Hb}$, FCOHb, FMethb, FHHb).
{1}
Page 2 of 12
$\mathbf{pCO_2}$ , $\mathbf{pO_2}$ , $\mathbf{pH}$ . Measurements of blood gases (PCO2, PO2) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances.
**Sodium.** Sodium measurements obtained by this device are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.
**Potassium.** Potassium measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.
**Chloride.** Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.
**Ionized calcium.** Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms).
**Glucose.** Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
**Lactate.** Lactic acid measurements that evaluate the acid-base status are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).
**Total hemoglobin.** Total hemoglobin measurements are used to determine the hemoglobin content of human blood.
**Oxyhemoglobin.** Oxyhemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia.
**Carboxyhemoglobin.** Carboxyhemoglobin measurements are used to determine the carboxyhemoglobin (the compound formed when hemoglobin is exposed to carbon monoxide) content of human blood as an aid in the diagnosis of carbon monoxide poisoning.
**Sulfhemoglobin.** Sulfhemoglobin measurements are used to determine the sulfhemoglobin (a compound of sulfur and hemoglobin) content of human blood as an aid in the diagnosis of sulfhemoglobinemia (presence of sulfhemoglobin in the blood due to drug administration or exposure to a poison).
3. Special condition for use statement(s):
None
4. Special instrument Requirements:
None
{2}
# H. Device Description
The Rapidlab 1200 Series system has the following features:
Compact design with self-contained reagent and wash cartridges that are easily replaced when empty.
Automatic calibration of the measurement sensors
Automatic sample aspiration that eliminates variability in sampling
Automatic QC sampling at customized intervals using the optional Automatic QC cartridge
High resolution touch screen that tilts for viewing information and making selection
Built-in removable storage media to copy patient, QC, and calibration data for storage, or for export to spreadsheet or database programs
Communication ports for connecting to external data management systems, such as the Rapidlink Data Management system or an LIS (laboratory information system)
Self-contained CO-oximetry sample chamber
# I. Substantial Equivalence Information:
1. Predicate device name(s):
Rapidlab 800 Series Analyzers; Rapidlab 400 Series Analyzers
2. Predicate K number(s):
K933373, K946206, K002738, K020616
3. Comparison with predicate:
Similarities & Differences
| Item | Rapidlab 1200 Series | Rapidlab 800 Series K9333731K946206 | Rapidpoint 400 Series K002738/K020616 |
| --- | --- | --- | --- |
| Measured Parameters | pH, PC02, p02, Na+, K+, Cl-, Ca++, Glucose, Lactate, CO-ox CO-oximetry parameters (tHb, F02Hb, FCOHb, FMethb, FHHb | pH, PC02, P02, Na+, K+, Cl-, Ca++, Glucose, Lactate, CO-ox CO-oximetry parameters (tHb, F02Hb, FCOHb, FMethb, FHHb | pH, PC02, p02, Na+, K+, Cl-, Ca++, Glucose, Lactate, Hct, CO-ox CO-oximetry parameters (tHb, F02Hb, FCOHb, FMethb, FHHb) |
| Calculated Parameters | Ca++ (7.4), 02 SAT(est), 502, Anion Gap, 02 CT, p02 (A-a), p02(a/A), p50, ct02(a-v), ct02([a-v]/a), V02, D02, RI(T), Qsp/Qt, Qsp/Qt(est), HC03 act, HC03 std, ctC02, BE(B), BE(ecf), p02/F,02, Ct02(a), ct02(v), Hct, p02(T), B02, pH(T), ct 02 (Hb), PC02(T) | Ca++ (7.4), 02 SAT(est), s02, Anion Gap, 02CT, P02 (A-a), P02 (a/A), p50, ct02(a-v), ct02([a-v]/a), V02, D02, RI(T), Qsp/Qt, Qsp/Qt(est), HC03 act, HC03 std, ctC02, BE(B), BE(ecf), p02/F,02, Ct02(a), ct02(v), Hct, p02(T), B02, pH(T), ct 02 (Hb), PC02(T) | Ca++ (7.4), 02 SAT(est), s02, Anion Gap, 02CT, P02 (A-a), P02 (a/A), p50, ct02(a-v), ct02([a-v]/a), V02, D02, RI(T), Qsp/Qt, Qsp/Qt(est), HC03 act, HC03 std, ctC02, BE(B), BE(ecf), p02/F,02, Ct02(a), ct02(v), Hct, p02(T), B02, pH(T), ct 02 (Hb), PC02(T) |
| Entered Parameters | Temp, tHb, Fi02, Flow, RespRate, Atm, Qt(T), Tonometry Time, Catheter Type, Sex, Patient ID, Sample | Temp, Date, Time, Sample ID, ctHb, Fi02, Qt, OBF, Flow, Resp Rate | Temp, tHb, Fi02, Flow, RespRate, Atm, Qt(T), Tonometry Time, Catheter Type, Sex, Patient ID, Sample ID, |
{3}
Page 4 of 12
| | ID, Accession Number, Oper ID, Patient Name, Phys. ID, Date of Birth, Age, Draw Date, Draw Time, S02 | | Accession Number, Oper ID, Patient Name, Phys. ID, Date of Birth, Age, Draw Date, Draw Time, S02 |
| --- | --- | --- | --- |
| Sample Volume | 1175 ul Syringe/Cap
95 ul Microsample (Syringe/Cap)
10 ml *Expired* Gas | 1175 ul Syringe/Cap
95 ul Microsample (Syringe/Cap)
10 ml *Expired* Gas | 100 ul Syringe/Cap |
| | | | |
| Calibration Method | Auto and Adjustable
On board, gas
tonometered reagents | Auto and Adjustable
On board reagents
w/external gas tanks | Auto
On board, gas tonometered
reagents |
| Electrode Maintenance | READY Sensors:
Maintenance Free | READY Sensors:
Maintenance Free | None Required |
| Display | Color Passive Matrix
LCD | Monochrome Passive
Matrix LCD | Color Passive Matrix LCD |
| Print Out | Roll Printer | Roll Printer with Take-up
Spool | Roll Printer |
| Data Management | On-board | On-board | On-board |
| Interface Ports | RS232C (2)
1 Parallel Port
1 USB Port
Ethernet 1 | RS232C (4)
1 Parallel Port | RS232C (2)
Ethernet (1) |
| Power | 100 - 240 VAC
50 - 60 Hz
With Power Switch | 100 - 240 VAC
50 - 60 Hz
No Power Switch | 100 - 240 VAC
50 - 60 Hz
With Power Switch |
| Size | 23"W x 22.5"H x 22.5"D | 28"W x 19"H x 20"D | 11.5"W x 21"H x 16"D |
| Weight | 65 lbs. | 82 lbs. | 34 lbs. |
J. Standard/Guidance Document Referenced (if applicable):
- ISO 14971:2000 Medical devices - Application of risk management to medical devices
- IEC (EN) 60601-1-2:1993 (Second Edition, 2001), Medical Electrical Equipment --Part 1: General Requirements for Safety; Electromagnetic Compatibility -- Requirements and Tests
- ISO 13485:1996 - Quality systems - Medical Devices - Particular requirements for the application of ISO 9001
- IEEE 1012:1998 - Standard for Software Verification and Validation. (Software)
- ISO/IEC 12207:1995 - Information Technology - Software Life Cycle Processes
{4}
Page 5 of 12
- AAMI/ANSI SW68:2001 - Medical device software Software life cycle processes
Capability Maturity Model version 1.3
Guidance Documents:
The following FDA Guidance documents were used in preparing this Premarket 510(k) Notification:
- Recognition and Use of Consensus Standards, Final Guidance for Industry and FDA Staff
- The Least Burdensome Provision of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for Industry and FDA
- Guidance for Industry In Vitro Diagnostic Chloride Test System
- Guidance for Industry In Vitro Diagnostic Sodium Test System
- Guidance for Industry In Vitro Diagnostic Potassium Test System
- Guidance for Industry In Vitro Diagnostic Glucose Test System
- Guidance for Industry In Vitro Diagnostic Bicarbonate/Carbon Dioxide Test System
- Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices
K. Test Principle:
The Rapidlab 1200 System uses measurement technology that is based on electrochemical, biochemical and optical phenomena. The device use potentiometry and amperometry methods for blood gas, electrolytes and metabolites to convert the potential generated by the sensor to an electrical signal which the system then converts to a value that represents that concentration of a specific analyte or substances in recognizable units of measurement.
Electrodes used for measurement in the Rapidlab 1200 systems are called sensors. Each sensor has a molecular or ion-specific substance of interest in a sample.
The Rapidlab 1200 series system CO-oximetry module utilizes spectral absorption by measuring the light from whole blood at several wavelengths. The measurement module detects and quantitates total hemoglobin and other related quantities in the sample.
The Rapidlink data management system program is a system accessory that enables the user to manage patient, quality control (QC), maintenance, and calibration data for Bayer Diagnostic blood gas systems and CO-oximeters, including the Rapidlab 1200.
The Rapidlab 1200 series system will interface with the Rapidlink information management system and/or will provide connect capability to hospital LIS/HIS systems via network interface ports.
L. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Precision on manual aqueous quality control materials was established using a minimum of three instruments for each Rapidlab 1200 system. At least four runs per instrument were made over four days for pH, pCO₂, and pO₂. At least 30 runs per instrument were made over 48 days for the CO-ox fractions. Two replicates of each
{5}
Page 6 of 12
control level were analyzed in each run. All assays available on the Rapidlab 1200 system were evaluated as appropriate.
b. Linearity/assay reportable range:
Linearity of the system was compared to the predicate device within the whole blood method comparison testing. Linear regression was performed for the system series. The regression graphs demonstrated equivalence to the predicate device.
c. Traceability (controls, calibrators, or method):
Quality control materials, both manual (RapidQC Complete) and automatic (AQC) were analyzed on the Rapidlab 1200 systems. Manual QC is performed by the operator based on their established laboratory QC procedures, while AQC is performed automatically by the system based on the QC frequency defined in the system software. The RapidQC Complete material is sealed in a glass ampule and was cleared under 510(k), k970956.
d. Detection limit:
Detection limits for the Rapidlab 1200 system are defined as the linear range of each assay. As part of the whole blood method comparison testing minimum and maximum test values were obtained. The minimum values obtained for each tested parameter are near the limit of detection for the system.
e. Analytical specificity:
Interference testing was performed to demonstrate the specificity of the RapidLab 1200 sensors.
The results from each of the studies were tabulated and the simple average effect was determined for each interfering compound. The effect of interference column demonstrates the apparent change in result as a function of introducing the interfering compound. In several instances multiple tests were performed on an interfering substance as well as several levels of interfering substance.
The effect of the potential interfering substance on results is summarized in the following table. The table shows the interference level tested along with the average change in blood results (test result spiked - control result unspiked) for each of the sensors.
| Analyte(units) | Interference | Interference Level Tested | Effect of Interference (Test-control) |
| --- | --- | --- | --- |
| pH (pH units) | Acetaminophen | 20 mg/dL | 0.000 |
| | Sodium Pentothal | 300 mg/dL | -0.009 |
| | Salicylic Acid | 20 mg/dL | 0.000 |
| | Acetyl Salicylic Acid | 50 mg/dL | -0.513 |
| PO_{2} (mm Hg) | Isoflurane | 3 % | 3.48 |
| | Halothane | 3 % | 0.20 |
| | Nitrous Oxide | 84% | 0.25 |
| PCO_{2} (mm Hg) | Ibuprofen | 40 mg/dL | 0.35 |
| | Sodium Pentothal | 300 mg/dL | 1.34 |
{6}
| Analyte (units) | Interference | Interference Level Tested | Effect of Interference (Test - control) |
| --- | --- | --- | --- |
| Na+(mmol/L) | Acetaminophen | 2 mg/dL | 0.00 |
| | Dobutamine | 20 mg/dL | 0.37 |
| | Dobutamine | 10 mg/dL | 0.15 |
| | Dobutamine | 5 mg/dL | 0.20 |
| | Vancomycin | 63 ug/dL | -0.23 |
| | Ofloxacin | 6 ug/dL | -0.14 |
| | Perphenazine | 1.25 ug/mL | 0.05 |
| | Sodium Pentothal | 300 mg/dL | -0.88 |
| K+(mmol/L) | Sodium Pentothal | 300 mg/dL | -0.016 |
| Cl-(mmol/L) | Heparin | 90 units/ml- | 0.5 |
| | Salicylic Acid | 30 mg/dL | 1.0 |
| | Salicylic Acid | 20 mg/dL | 0.7 |
| | Acetylsalicylic Acid | 50 mg/dL | 0.5 |
| | Acetaminophen | 2 mg/dL | 0.0 |
| | Sodium Pentothal | 300 mg/dL | -1.0 |
| Ca++(mmol/L) | Acetaminophen | 2 mg/dL | -0.03 |
| | Ibuprofen | 40 mg/dL | -0.03 |
| | Salicylic Acid | 20 mg/dL | -0.04 |
| | Salicylic Acid | 30 mg/dL | -0.40 |
| | Sodium Pentothal | 300 mg/dL | -0.01 |
| | Acetyl Salicylic Acid | 50 mg/dL | 0.04 |
| | Acetyl Salicylic Acid | 30 mg/dL | 0.01 |
| | Acetyl Salicylic Acid | 15 mg/dL | 0.01 |
| Glucose (mg/dL) | Acetaminophen | 2 mg/dL | -11.8 |
| | Heparin | 90 units/ml | 7.8 |
| | Salicylic Acid | 30 mg/dL | -0.5 |
| | Salicylic Acid | 20 mg/dL | -0.3 |
| | Ethanol | 350 mg/dL | -1.5 |
| | Dopamine | 10 mg/dL | -12.6 |
| | Dopamine | 5 mg/dL | 12.5 |
| | Dobutamine | 20 mg/dL | -9.5 |
| | Dobutamine | 10 mg/dL | -5.5 |
| | Dobutamine | 5 mg/dL | -2.0 |
| | Acetylsalicylic Acid | 50 mg/dL | -1.5 |
| | Sodium Pentothal | 300 mg/dL | -0.9 |
| | P02 | 25-85 mm Hg | -1.0 |
| Lactate (mmol/L) | Chlorpromazine | 17 mg/dL | <+/-0.3 |
| | Dopamine | 1 mg/dL | <+/-0.3 |
| | Ethanol | 350 mg/dL | <+/-0.3 |
| | Salicylate | 50 mg/dL | <+/-0.3 |
| | Sodium Nitroprusside | 70 mg/dL | <+/-0.3 |
| | Thiocyanate | 80 mg/dL | <+/-0.3 |
| | Heparin | 20,000 U/dL | <+/-0.3 |
| | Epinephrine | 2 mg/dL | <+/-0.3 |
| | Norepinephrine | 2 mg/dL | <+/-0.3 |
| | Phenobarbital | 15 mg/dL | <+/-0.3 |
| | Glutamate | 16 mg/dL | <+/-0.3 |
| | Hetastarch | 30% | <+/-0.3 |
| | Acetoacetate | 40 mg/dL | <+/-0.3 |
| | Ascorbate | 8 mg/dL | <+/-0.3 |
{7}
| Dilantin | 14 mg/dL | <+/-0.3 |
| --- | --- | --- |
| Bilirubin (Direct) | 30 mg/dL | <+/-0.3 |
| Bilirubin (Total) | 35 mg/dL | <+/-0.3 |
| Creatinine | 30 mg/dL | <+/-0.3 |
| Hydroxybutyrate | 200 mg/dL | <+/-0.3 |
| Urea | 500 mg/dL | <+/-0.3 |
| Guaiacol | 5 mg/dL | <+/-0.3 |
| Pyruvate | 9 mg/dL | <+/-0.3 |
| Theophylline | 9 mg/dL | <+/-0.3 |
| Penicillamine | 25 mg/dL | <+/-0.3 |
| Isoniazid | 2 mg/dL | <+/-0.3 |
| Uric Acid | 10 mg/dL | <+/-0.3 |
| Citrate | 1000 mg/dL | <+/-0.3 |
| Potassium Oxalate | 1000 mg/dL | <+/-0.3 |
| EDTA | 800 mg/dL | <+/-0.3 |
| Sodium Fluoride | 1000 mg/dL | 1.0 |
| Sodium Fluoride/ | 1000 mg/dL | 1.0 |
| Potassium Oxalate | | |
| Acetaminophen | 2 mg/dL | 0.35 |
Interference Testing for RapidLab 1200 CO-oximetry was performed to demonstrate the specificity of the RapidLab 1200 CO-oximterry module.
The mean effect was calculated as the spiked mean minus the control mean. The probability of the mean effect being zero was calculated, and those with less than a $5\%$ chance $(p < 0.05)$ were considered statistically significant. For those effects which were statistically significant, a mean effect $>0.5\mathrm{g / dL}$ for tHb or $>1.0\%$ for the CO-ox fractions was considered clinically significant. The reported effects for methylene blue at 25 and $40~\mathrm{mg / L}$ are the simple mean effect (spiked mean - control mean).
For sulfhemoglobin, the mean effect was corrected using the difference observed between the spike and control from an additional reference method (gas chromatography or mass spectrophotometry depending on analyte) which was not subject to interference. That is, sample preparation differences alone, between the spiked and control
{8}
Page 9 of 12
samples, accounted for some of the observed differences and by subtracting out that contribution using the reference method, the true interference can be estimated.
Interference Testing Results for tHb, F0₂Hb, FCOHb, FMetHb, and FHHb
| Potential Interferent | Level Tested | Effect of Interference |
| --- | --- | --- |
| Lipid | 5 % intra-Lipid in serum | No effect |
| Bilirubin | 40 mg/dL | No effect |
| Fetal Hemoglobin | 20,40,85% | No effect |
| CyanMethemoglobin | 10% | No effect |
| Beta-carotene | 40 mg/dL | No effect |
| Hemolysis | 10 % volume | No effect |
| Evans Blue | 5 mg/L | No effect |
| Indocyanine Green | 5 mg/dL | No effect |
| Methylene Blue | 25 mg/dL | F02Hb -1.2 FCOHb +1.3 |
| Methylene Blue | 40 mg/dL | F02Hb -2.0 FCOHb +2.0 |
| Sulfhemoglobin | 10% | tHb -0.8g/dL F0₂Hb -6.7
FCOHb +3.6 FMetHb +1.4
FHHb +1.7 |
f. Assay cut-off:
The assay cut-off is established as the linearity range of the Rapidlab 1200 System Series for each analyte.
2. Comparison studies:
a. Method comparison with predicate device:
For each of the runs performed on the Rapidlab 1200 systems, the same samples analyzed using the predicate device, the Rapidlab 800. Simple linear regression was employed to determine the method comparison statistics. The test range for each sample type is reported in the columns titled minimum and maximum. The gases were regressed against their theoretical gas values while pH used the corresponding 800 results.
Example of method comparison tests are represented as following by Rapidlab 1260: For each of the runs performed on the RapidLab 1260, the same samples were analyzed using the predicate device, the RapidLab865. Simple linear regression was employed to determine the method comparison statistics below. The test range for each sample type is reported in the columns titled Min and Max. The gasses were regressed against their theoretical gas values while pH, electrolytes, and metabolites all used the corresponding 865 results. Refer to Tables 1-9 for a summary of the method comparison results.
{9}
Table 1: 1260 Whole Blood Method Comparison - pH
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 53 | 0.992 | 0.050 | 0.008 | 0.999 | 6.977 | 7.603 |
| Micro | 53 | 0.960 | 0.286 | 0.007 | 0.999 | 7.015 | 7.594 |
| Syringe | 52 | 0.980 | 0.145 | 0.006 | 0.999 | 7.020 | 7.602 |
| pH Only | 53 | 0.983 | 0.121 | 0.007 | 0.999 | 7.029 | 7.632 |
Table 2: 1260 Whole Blood Method Comparison - pCO2
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 72 | 0.976 | 1.368 | 6.457 | 0.980 | 12.5 | 152.1 |
| Micro | 72 | 0.974 | 1.099 | 6.844 | 0.978 | 12.6 | 164.5 |
| Syringe | 72 | 0.981 | 1.231 | 4.909 | 0.989 | 13.6 | 154.3 |
Table 3: 1260 Whole Blood Method Comparison - pO2
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 72 | 1.025 | -0.837 | 19.950 | 0.992 | 27.5 | 797.3 |
| Micro | 71 | 0.987 | 3.474 | 16.420 | 0.994 | 27.5 | 737.0 |
| Syringe | 72 | 1.000 | 3.470 | 16.520 | 0.994 | 27.3 | 749.4 |
Table 4: 1260 Whole Blood Method Comparison - Na
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 43 | 1.039 | -2.800 | 2.315 | 0.991 | 106.6 | 184.5 |
| Micro | 54 | 0.995 | 0.733 | 1.655 | 0.995 | 106.2 | 180.3 |
| Syringe | 54 | 0.967 | 3.696 | 1.296 | 0.997 | 107.7 | 177.5 |
Table 5: 1260 Whole Blood Method Comparison - K
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 54 | 1.009 | 0.010 | 0.106 | 0.999 | 1.11 | 9.60 |
| Micro | 53 | 0.986 | 0.093 | 0.142 | 0.998 | 1.21 | 9.82 |
| Syringe | 54 | 0.992 | 0.024 | 0.126 | 0.998 | 1.03 | 9.51 |
Table 6: 1260 Whole Blood Method Comparison - Ca
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 53 | 1.054 | -0.083 | 0.127 | 0.991 | 0.42 | 4.98 |
| Micro | 53 | 1.098 | -0.146 | 0.150 | 0.988 | 0.42 | 5.16 |
| Syringe | 52 | 1.059 | -0.084 | 0.122 | 0.991 | 0.51 | 5.02 |
Table 7: 1260 Whole Blood Method Comparison - Cl
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 43 | 0.979 | 3.706 | 2.790 | 0.985 | 76 | 150 |
| Micro | 52 | 1.020 | -2.110 | 2.354 | 0.989 | 75 | 150 |
| Syringe | 52 | 1.001 | -0.354 | 2.700 | 0.985 | 77 | 143 |
Table 8: 1260 Whole Blood Method Comparison - Glucose
| Mode | N | Slope | Intercept | RMSE | R Square | Min | Max |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Capillary | 44 | 1.049 | -3.028 | 20.957 | 0.991 | 30 | 710 |
| Micro | 54 | 1.021 | -4.840 | 17.521 | 0.994 | 37 | 698 |
| Syringe | 54 | 1.015 | -8.892 | 16.097 | 0.995 | 38 | 688 |
{10}
Table 9: 1260 Whole Blood Method Comparison - Lactate
| Mode | N | Slope | Test Range | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | | Intercept | RMSE | R Square | Min | Max |
| Capillary | 54 | 1.123 | -0.570 | 1.401 | 0.970 | 1.5 | 29.3 |
| Micro | 54 | 1.145 | -0.643 | 2.081 | 0.939 | 1.4 | 31.6 |
| Syringe | 54 | 1.000 | -0.256 | 1.393 | 0.968 | 1.4 | 28.9 |
b. Matrix comparison: NA
3. Clinical studies:
a. Clinical sensitivity: None stated
b. Clinical specificity: None stated
c. Other clinical supportive data (when $a$ and $b$ are not applicable): None
4. Clinical cut-off: None stated
5. Expected values/Reference range: The expected values of each parameter are within reportable range for the various measured and calculated parameters are provided in the Operator's Manual.
M. Instrument Name:
Bayer Rapidlab 1200 System Series
N. System Descriptions:
1. Modes of Operation: The system will use a reagent cartridge, wash cartridge, automatic QC cartridge and Rapidlab 800 sensor.
2. Software:
FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:
Yes ☐ or No ☑
3. Sample Identification: Bar code
4. Specimen Sampling and Handling: Automatic sample aspiration, Self-contained CO-oximetry sample chamber
5. Assay Types: The Rapidlab 1200 System uses measurement technology that is based on electrochemical, biochemical and optical phenomena. The device use potentiometry and amperometry methods for blood gas, electrolytes and metabolites to convert the potential generated by the sensor to an electrical signal which the system then converts to a value that represents that
{11}
Page 12 of 12
concentration of a specific analyte or substances in recognizable units of measurement.
6. **Reaction Types:**
- Ion selective electrode – Potassium, Chloride, Sodium, Calcium, and pH
- Potentiometric – pCO2
- Amperiometric – pO2
- Enzymatic – Lactic Acid, Glucose
- Spectral absorbency – CO-oximetry parameters
7. **Calibration:**
Calibration of the Rapidlab 1200 Series systems occurs automatically at defined integrals and requires no operator action.
8. **Quality Control:**
The Rapidlab 1200 system offers three options for quality control (QC) analysis: required QC analysis, automatic QC analysis, and unscheduled QC analysis. The RapidQC Complete material is sealed in a glass sample ampule and was cleared under K970956.
**O. Other Supportive Instrument Performance Characteristics Data Not Covered In The "L. Performance Characteristics" Section Of The SE Determination Decision Summary.**
N/A
**P. Conclusion:**
Based upon the information provided, I recommend that the Rapidlab 1200 System be found substantially equivalent to the respective predicate devices.
